PRTN3 and autoimmune disease: The case report is the first to present a dramatic autoimmune disorder following cancer immunotherapy characterized by multiple specific autoantibodies, including anti-GBM, PR3, MPO, dsDNA, PL-7 and Ku antibodies, without notable clinical involvement.